NVSNovartis PharmaceuticalsRunning, no new patients
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 210 (final count)
- Started
- Dec 17, 2021
- Main results expected
- Jan 28, 2027
- Fully finished
- Feb 26, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS) based on BIRC assessments and using RECIST v1.1 criteria
Measured over: From randomization to date of the first documented progression or death due to any cause, assessed up to a maximum duration of 60 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05038735 · record last updated 2026-09-29 · checked 2026-11-09 15:47 UTC